Precigen, Inc. (NASDAQ:PGEN) Receives $6.33 Average PT from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.00.

PGEN has been the topic of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Precigen in a report on Thursday.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Iridian Asset Management LLC CT boosted its holdings in Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after purchasing an additional 1,706,815 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after acquiring an additional 149,829 shares during the last quarter. State Street Corp raised its stake in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after acquiring an additional 29,253 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 127,467 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Precigen by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after purchasing an additional 130,500 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Price Performance

NASDAQ:PGEN opened at $1.39 on Monday. The stock has a market cap of $407.09 million, a PE ratio of -2.53 and a beta of 1.65. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $1.93. The stock’s 50-day moving average is $0.94 and its two-hundred day moving average is $1.05.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.